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Conclusion YF476 is a promising new medical treatment for type I
gastric neuroendocrine tumours. It appears to be well tolerated with
no observed toxicity. Further trials of YF476 involving more
prolonged treatment regimes are therefore warranted in this
condition.
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Introduction Meta-analysis of published single hospital series
including 1977 subjects suggests that 14% of gastric cancer (GC)
subjects have had an upper gastrointestinal endoscopy (OGD) up to
3 years previously that failed to diagnose their GC (50% in the
12 months before diagnosis and 50% 1e3 years before diagnosis).
Methods All patients with GC in the THIN general practice data-
base covering 5 million UK subjects were examined. A nested case-
control study was performed with cases subjects who underwent
OGD 1e5 years prior to their OGD that diagnosed GC and controls
subjects who did not undergo OGD 1e5 years prior to their
diagnostic OGD.
Results 5473 GC were available for analysis (3402 males (62%),
mean age 71 years), with follow-up of 46 779 subject years. 169
(3.1%, 98 males (58%), mean age 71 years) had an OGD which failed
to diagnose GC between 1 and 5 years prior to diagnosis of GC, out
of whom 128 (2.3%) had OGD between 1 and 3 years before and 41
(0.7%) had an OGD between 3 and 5 years before diagnosis. There
were 56 primary care consultations with symptoms pertaining to
oesophago-gastric cancer between 1 and 5 years prior to diagnosis of
GC (dyspepsia (n) 51, anaemia 9, weight loss 12, dysphagia 3), of
which all underwent OGD. No subject who had an OGD that did
not diagnose cancer was on proton pump inhibitor (PPI) therapy in
the year prior to OGD and 49 (0.9%) of subjects were on PPI therapy
in the year prior to being diagnosed with GC. Logistic regression
analysis of subjects who had an OGD that failed to diagnose cancer
and those that did not, failed to identify any speciﬁc predictive
factors (age 1.0 (0.99e1.01), p¼0.99), sex 0.84 (0.61e1.14), p¼0.26),
related to an OGD that failed to diagnose GC.
Conclusion Missing GC at OGD is, reassuringly, less than half as
common as previous much smaller studies in secondary care have
suggested. PPI therapy does not contribute to missing GC at OGD.
Advances in endoscopy and selection bias in previous studies may
account for these differences.
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Introduction Current diagnostic practice for paediatric CD in the UK
includes increased screening of family members and at- risk groups
for example, diabetes mellitus.
Aims To identify all incident cases of CD in SE Scotland over the 20-
year period of 1990e2009 to assess trends in incidence, sympto-
matology, age at diagnosis and the impact of active screening of at-
risk groups. Utility of routine laboratory tests at diagnosis was also
evaluated (2005e2009 diagnoses only).
Methods A retrospective review of case notes, pathology databases,
endoscopy and patient records was performed for all children diag-
nosed with CD <16 years from 1990 to 2009 on duodenal biopsy in
SE Scotland (at-risk population group of 233 000 aged <16 years).
Data were age-sex standardised and analysed in 5-year epochs, with
Poisson regression models used to calculate changes in incidence over
time.
Results 266 biopsy positive children were diagnosed from 1990 to
2009 with an increase in incidence from 1.8 (95% CI 1.1 to 2.7) to
11.7 (95% CI 9.8 to 13.9) per 100 000 children aged <16 years during
the 1990e1994 and 2005e2009 epochs respectively (p¼0.001). The
median age (IQR) at diagnosis also increased signiﬁcantly from 29
(16e53) months to 90 (53e132) between these epochs (p<0.0001),
and non-classical presentation (children with a mono-symptomatic
presentation and those with extra-intestinal symptoms for example,
fatigue, pallor, irritability) increased signiﬁcantly from 5% to 21%
respectively (p¼0.008). Additionally, 7% of children were diagnosed
through targeted screening in 1990e1994 compared to 23% in
2005e2009 (p¼0.002). When cases identiﬁed via active screening or
with non-classical symptoms were removed, a signiﬁcant rise from
1.51 (95% CI 0.91 to 2.38) in 1990e1994 to 6.59 (95% CI 5.17 to
8.28) in 2005e2009 (p¼0.006) remained. Routine blood inves-
tigations demonstrated that over 25% were anaemic and over 50%
were iron deﬁcient at presentation in 2005e2009.
Conclusion The incidence of paediatric CD has increased 6.5-fold
over the last 20 years in SE Scotland. Children are older at diagnosis,
presenting with fewer classical and more varied symptoms, and
with iron deﬁciency anaemia the commonest laboratory abnor-
mality. We show that both increased screening of at-risk groups and
a lower threshold for serological screening (as a result of greater
clinician awareness of the condition’s heterogeneic nature) do not
fully explain the overall rise in incidence.
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Introduction We have previously shown that entire ﬁelds of dysplasia
in the human stomach are derived from a single mutated, meta-
plastic gland.1 This suggests that intestinal metaplasia (IM) can be
considered a ﬁeld defect among which dysplasia can arise and this
would indicate that adenocarcinomas derived from such dysplasia
would also be clonal. Recent work published by our laboratory has
indicated that familial adenomatous polyposiseassociated colorectal
adenomas as well as some sporadic lesions2 and dysplasia within
Barrett’s oesophagus3 are polyclonal. There is therefore a need to
ascertain the clonality of gastric adenocarcinomas (GA).
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